Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

  “The window to shape the oral GLP-1 market is open now….” Early-stage discussions with several multinational pharmaceutical companies currently underway   Kelowna, British Columbia – March 24, 2026 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms provides this update of developments within the glucagon-like peptide-1 (“GLP-1”) market. Lexaria has been listening and responding to the concerns of those using GLP-1 drugs, ...